Our biotechnology company is developing therapies based on cellular mechanisms identified by a world-renowned research group
Concept and link to cancer
Dependence Receptors are trans-membrane proteins that receive signals and transmit them inside cells. They play a key role in the control of tumor development and can be considered as tumor suppressors.
Therapeutic strategy
Based on the concept of Dependence Receptors, the therapeutic strategy of NETRIS Pharma is to block the interaction between DRs and their ligands to restore the tumor suppressing functions.
Research
NETRIS Pharma identifies the modifications of Dependence Receptors in cancer, perform proof of concept studies and develop monoclonal antibodies as drug candidates.
Located in Léon Bérard Cancer Center (Lyon, France),
NETRIS Pharma is a unique model of a biotechnology company
integrated within a comprehensive cancer center
